Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors
AFM24 的临床前评估，这是一种针对 EGFR 阳性肿瘤的新型 CD16A 特异性先天免疫细胞接合剂
期刊:MAbs
影响因子:5.6
doi:10.1080/19420862.2021.1950264
Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Michael Kluge, Michael Damrat, Jens Pahl, Ute Schniegler-Mattox, Thomas Mueller, Ivica Fucek, Kristina Ellwanger, Michael Tesar, Torsten Haneke, Joachim Koch, Martin Treder, Wolfgang Fischer, Erich Rajkovic
